Fairmount Funds Management LLC and related parties report a 6.3% stake in Enliven Therapeutics, Inc. This Amendment No. 4 updates prior Schedule 13G filings and shows 3,711,444 shares of the issuer's common stock are reported as beneficially owned on a shared basis by Fairmount Funds Management LLC, Fairmount Healthcare Fund II L.P., and two managing members, Peter Harwin and Tomas Kiselak. The percentage is calculated using 58,959,717 shares outstanding as of June 16, 2025.
The filing clarifies that Fund II directly owns the reported shares but has delegated sole voting and dispositive power to Fairmount; Fund II disclaims beneficial ownership for Section 13(d) purposes because the delegation cannot be revoked on less than 61 days' notice. Signatures and a joint filing agreement dated August 14, 2025, accompany the amendment.
Polar Capital Holdings Plc, Polar Capital LLP and Polar Capital Funds PLC - Biotechnology Fund report beneficial ownership of 2,536,881 shares of Enliven Therapeutics common stock, representing 5.17% of the class based on 49,069,258 shares outstanding as reported by the issuer on May 14, 2025. The filing is a Schedule 13G and shows the reporting persons hold sole voting and sole dispositive power over the reported shares with no shared voting or dispositive power.
The filing includes a joint filing statement (Exhibit I) and a certification that the securities were not acquired to change or influence control of the issuer, indicating passive disclosure under the Schedule 13G rules.
Enliven Therapeutics, Inc. filed a shelf registration describing an offering program for common stock, preferred stock, debt securities and other instruments and includes a Sales Agreement prospectus supplement for up to $200.0 million of common stock under an Open Market Sale Agreement with Jefferies LLC. The company is an emerging growth, clinical-stage biopharmaceutical company listed on Nasdaq under ELVN.
Enliven emphasizes its lead program, ELVN-001, a selective BCR-ABL inhibitor for chronic myeloid leukemia. Updated ENABLE Phase 1 data reported that 25 of 53 (47%) evaluable patients reached major molecular response (MMR) by 24 weeks; 13 of 41 (32%) achieved MMR and 12 of 12 (100%) maintained MMR. ELVN-001 was described as well tolerated. The company is prioritizing ELVN-001 and is exploring strategic alternatives for ELVN-002, which it does not intend to advance beyond 2025.
Enliven Therapeutics (ELVN) is a clinical-stage biopharmaceutical company focused on small-molecule oncology programs. As of June 30, 2025, the company held $119.4 million in cash and $371.1 million in marketable securities, totaling approximately $490.5 million available to fund operations, which management expects will be sufficient for at least 12 months. Total assets were $503.9 million and stockholders' equity was $488.5 million.
The company reported a net loss of $25.3 million for the three months ended June 30, 2025 and a net loss of $53.9 million for the six months ended June 30, 2025, driven by $21.5 million of R&D and $7.1 million of G&A expense in the quarter. Accumulated deficit totaled $297.4 million. During June 2025 Enliven completed a public offering that raised aggregate gross proceeds of $230.0 million (before issuance costs) through sales of common stock and pre-funded warrants, increasing shares outstanding to about 59.2 million.
The company continues to advance ELVN-001 toward a pivotal trial, is exploring strategic alternatives for ELVN-002 and does not intend to pursue ELVN-002 development beyond 2025. Cash used in operating activities for the first half of 2025 was $41.2 million, and investing activity reflected significant purchases of marketable securities.
Enliven Therapeutics, Inc. (ELVN) Chief Operating Officer Anish Patel reported sales of the issuer's common stock on 08/07/2025 via Form 4. The filing states the sales were effected pursuant to a Rule 10b5-1 trading plan adopted September 30, 2024, and involved The Patel / Dong Family Trust, for which Mr. Patel serves as trustee. The report discloses weighted-average sale prices of $18.1969 and $18.9297, with execution price ranges of $17.78–$18.73 and $18.805–$19.16 noted in the footnotes. The Form reports indirect beneficial ownership figures of 290,380 and 289,975 shares held by the trust following the transactions, and the filing was signed by power of attorney on 08/11/2025.